Apellis Pharmaceuticals
Australia - Hawthorn East
Pharmaceutical2 H-1B visas (FY2023)Focus: Cyclic peptide analog
Apellis Pharmaceuticals is a life sciences company focused on Cyclic peptide analog.
Neurology
Open Jobs
25
Products & Portfolio (2)
Pipeline & Clinical Trials
Geographic Atrophy Long-Terms Outcomes Study
Geographic AtrophyClinical Trials (1)
NCT06499571Geographic Atrophy Long-Terms Outcomes Study
N/APegcetacoplan
C3GClinical Trials (1)
NCT04729062C3G/Primary IC-MPGN EAP
N/AVirtual Reality
Age-Related Macular DegenerationClinical Trials (1)
NCT06241625Virtual Reality Based Vision Test in Patients With AMD
N/APegcetacoplan
Geographic AtrophyClinical Trials (1)
NCT06161584A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
N/APEGCETACOPLAN
Geographic AtrophyClinical Trials (1)
NCT03777332Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
Phase 1Pegcetacoplan
Paroxysmal Nocturnal Hemoglobinuria (PNH)Clinical Trials (1)
NCT02264639A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
Phase 1Pegcetacoplan
Paroxysmal Nocturnal HemoglobinuriaClinical Trials (1)
NCT02588833Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
Phase 1Pegcetacoplan
Neovascular Age-Related Macular DegenerationClinical Trials (1)
NCT02461771Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Phase 1Pegcetacoplan
Neovascular Age-related Macular DegenerationClinical Trials (1)
NCT03465709Pegcetacoplan (APL-2) in Neovascular AMD
Phase 1/2APL-9
COVIDClinical Trials (1)
NCT04402060A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
Phase 1/2Phase 2
Clinical Trials (1)
NCT03226678Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Phase 2Pegcetacoplan
Amyotrophic Lateral SclerosisClinical Trials (1)
NCT04579666MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
Phase 2Pegcetacoplan
C3GClinical Trials (1)
NCT04572854Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Phase 2Pegcetacoplan
Geographic AtrophyClinical Trials (1)
NCT02503332Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
Phase 2APL-3007, pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular DegenerationClinical Trials (1)
NCT07215390A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Phase 2Pegcetacoplan
PNHClinical Trials (1)
NCT03593200A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
Phase 2Pegcetacoplan
Transplant-Associated Thrombotic MicroangiopathyClinical Trials (1)
NCT05148299A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
Phase 2APL-2
IgA NephropathyClinical Trials (1)
NCT03453619Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Phase 2Pegcetacoplan
Paroxysmal Nocturnal Hemoglobinuria (PNH)Clinical Trials (1)
NCT04901936A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2APL2
FSGSClinical Trials (1)
NCT07213960A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Phase 2/3Pegcetacoplan
Paroxysmal Nocturnal HemoglobinuriaClinical Trials (1)
NCT03500549Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3Pegcetacoplan
PNHClinical Trials (1)
NCT03531255Pegcetacoplan Long Term Safety and Efficacy Extension Study
Phase 3Pegcetacoplan
C3GClinical Trials (1)
NCT05809531An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Phase 3APL-2, Pegcetacoplan
Geographic Atrophy Secondary to Age-related Macular DegenerationClinical Trials (1)
NCT07214740Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Phase 3Pegcetacoplan
C3GClinical Trials (1)
NCT05067127Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Phase 3APL-2
Geographic AtrophyClinical Trials (1)
NCT03525600Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Phase 3Pegcetacoplan
Delayed Graft FunctionClinical Trials (1)
NCT07020832A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Phase 3APL-2
Geographic AtrophyClinical Trials (1)
NCT03525613A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Phase 3Phase 3
Clinical Trials (1)
NCT04085601A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
Phase 3Phase 3
Clinical Trials (1)
NCT04770545An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Phase 3Open Jobs (25)
Account Manager, Nephrology (Raleigh)
Field, US
5d ago
$156K - $234K/yr
Account Manager, Nephrology (Atlanta)
Field, US
5d ago
$156K - $234K/yr
Account Manager, Nephrology (Charleston)
Field, US
5d ago
$156K - $234K/yr
Sr. Executive Assistant, Business Development, Strategy & Program Management
Waltham, US
6d ago
$94K - $141K/yr
Senior Director, Biostatistics
Waltham, US
1w ago
$238K - $357K/yr
HRIS Analyst
Waltham, US
Human Resources1w ago
$77K - $116K/yr
Territory Business Manager – Ophthalmology (North Jersey)
Field, US
Commercial2w ago
$160K - $240K/yr
Director, Patient Marketing – Ophthalmology
Waltham, US
Commercial2w ago
$200K - $300K/yr
Senior Director, Medical Safety Science
Waltham, US
Regulatory Affairs2w ago
$245K - $367K/yr
Finance Systems Manager
Waltham, US
Finance2w ago
$124K - $185K/yr
Senior Manager, Statistical Programming
Remote
2w ago
$164K - $246K/yr
Senior Director, Market Access, Corporate Accounts
Field, US
Commercial2w ago
$241K - $361K/yr
Manager, Medical Strategy Operations
Waltham, US
3w ago
Territory Business Manager – Ophthalmology (Seattle)
Field, US
3w ago
$160K - $240K/yr
Territory Business Manager - Ophthalmology (Columbia, SC)
Field, US
3w ago
$160K - $240K/yr
Sr Mgr, Drug Substance Process Development
Waltham, US
1mo ago
$159K - $239K/yr
Sr. Manager, DS Process Development - CMC
Zug, CH
1mo ago
Manager, Manufacturing Technical – Drug Product
Waltham, US
1mo ago
$114K - $171K/yr
Director, Regulatory Affairs
Waltham, US
1mo ago
$196K - $294K/yr
Director, Compensation
Waltham, US
1mo ago
$200K - $270K/yr
Executive Director, People Experience Partnership and G&A HRBP
Waltham, US
2mo ago
$250K - $375K/yr
Medical Science Liaison - New South Wales
Field, AU
2mo ago
Sales Manager - Germany
Field, DE
3mo ago
Key Account Manager - Germany
Field, DE
3mo ago
Medical Science Liaison Germany - North
Field, DE
3mo ago
Interview Prep Quick Facts
Portfolio: 2 approved products, 30 clinical trials
Top TAs: Nephrology, Ophthalmology, Rare Diseases
H-1B (2023): 2 approvals
Open Roles: 25 active jobs
Portfolio Health
Peak2 (100%)
2 total products
Therapeutic Area Focus
Nephrology
6 pipeline
Ophthalmology
5 pipeline
Rare Diseases
2 marketed
Immunology
2 pipeline
Infectious Diseases
1 pipeline
Neurology
1 pipeline
Respiratory
1 pipeline
Marketed
Pipeline
Hiring Trend
Slowing Down
25
Open Roles
+5
Added
-11
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub